An Open-label, Multicenter Phase Ib Study of the Safety and Tolerablility of Atezolizumab (ANTIPD-L1 Antibody) Administered in Combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors
A Study for Patients with Solid Tumors Using Study Drug Atezolizumab
Sponsor: Genentech, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ7567
U.S. Govt. ID: NCT02715531
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This purpose of this study is to evaluate the safety and tolerability of study drug atezolizumab when administered with bevacizumab and FOLFOX in patients with gastric cancer. This study will also evaluate the safety and tolerability of atezolizumab administered with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
This study is closed
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Have you been diagnosed with gastric cancer or metastatic pancreatic cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE